Switching from etanercept to adalimumab is effective and safe: Results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept

British Journal of Dermatology

Volumn 163, Issue 4, 2010, Pages 838-846

  Van Lumig P P M ^a   Lecluse, L L A ^b   Driessen, R J B ^a   Spuls, P I ^b   Boezeman, J B ^a   Van De Kerkhof, P C M ^a   De Jong, E M G J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

adalimumab; efficacy; etanercept; psoriasis; safety; treatment

Indexed keywords

ADALIMUMAB; CYCLOSPORIN A; DITHRANOL; ETANERCEPT; ETRETIN; FUMARIC ACID; METHOTREXATE;

ACTINIC KERATOSIS; ADULT; ARTHROPATHY; ARTICLE; BASAL CELL CARCINOMA; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EAR DISEASE; ENDOCRINE DISEASE; ERYSIPELAS; EYE DISEASE; EYE INFECTION; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL INFECTION; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; LOWER RESPIRATORY TRACT INFECTION; MALAISE; MALE; MUSCLE DISEASE; PNEUMONIA; PRECANCER; PRIORITY JOURNAL; PSORIASIS; SHOULDER FRACTURE; SIDE EFFECT; SKIN DISEASE; SKIN INFECTION; SQUAMOUS CELL CARCINOMA; TENDON RUPTURE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; WEIGHT REDUCTION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 77957021919     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.09950.x     Document Type: Article

References (26)

1. Coates LC, Cawkwell LS, Ng NW et al. Sustained response to long-term biologics and switching in psoriatic arthritis: results from real life experience. Ann Rheum Dis 2008 67 : 717 719.
2. Haitz KA, Kalb RE. Infliximab in the treatment of psoriasis in patients previously treated with etanercept. J Am Acad Dermatol 2007 57 : 120 125.
3. Papoutsaki M, Chimenti MS, Costanzo A et al. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics. J Am Acad Dermatol 2007 57 : 269 275.
4. Pitarch G, Sanchez-Carazo JL, Mahiques L et al. Efficacy of etanercept in psoriatic patients previously treated with infliximab. Dermatology 2008 216 : 312 316.
5. Ryan C, Kirby B, Collins P et al. Adalimumab treatment for severe recalcitrant chronic plaque psoriasis. Clin Exp Dermatol 2009 34 : 784 788.
6. Van L, Modi SV, Yang DJ et al. Sustained efficacy and safety of adalimumab in psoriasis treatment: a retrospective study of 49 patients with and without a history of TNF-alpha antagonist treatment. Arch Dermatol 2008 144 : 804 806.
7. Martyn-Simmons C, Green L, Ash G et al. Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation. J Eur Acad Dermatol Venereol 2009 23 : 1394 1397.
8. Lecluse LL, de Groot M, Bos JD et al. Experience with biologics for psoriasis in daily practice: switching is worth a try. Br J Dermatol 2009 161 : 948 951.
9. Berends MA, Driessen RJ, Langewouters AM et al. Etanercept and efalizumab treatment for high-need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice. J Dermatolog Treat 2007 18 : 76 83.
10. de Groot M, Appelman M, Spuls PI et al. Initial experience with routine administration of etanercept in psoriasis. Br J Dermatol 2006 155 : 808 814.
11. Driessen RJ, Boezeman JB, van de Kerkhof PC et al. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome. Br J Dermatol 2009 160 : 670 675.
12. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978 157 : 238 244.
13. Keystone E, Fleischmann R, Emery P et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007 56 : 3896 3908.
14. van Vollenhoven RF. Switching between biological agents. Clin Exp Rheumatol 2004 22 : S115 21.
15. Mease PJ, Ory P, Sharp JT et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 2009 68 : 702 709.
16. Pitarch G, Sanchez-Carazo JL, Mahiques L et al. Treatment of psoriasis with adalimumab. Clin Exp Dermatol 2007 32 : 18 22.
17. Lecluse LL, Driessen RJ, Spuls PI et al. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol 2010 146 : 127 132.
18. Rubbert-Roth A, Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther 2009 11 (Suppl. 1 S1.
19. van Vollenhoven RF. Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue. Ann Rheum Dis 2007 66 : 849 851.
20. Wolfe F, Michaud K, Dewitt EM. Why results of clinical trials and observational studies of antitumour necrosis factor (anti-TNF) therapy differ: methodological and interpretive issues. Ann Rheum Dis 2004 63 (Suppl. 2 ii13 17.
21. Blom M, Kievit W, Fransen J et al. The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis. J Rheumatol 2009 36 : 2171 2177.
22. Gordon KB, Langley RG, Leonardi C et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006 55 : 598 606.
23. Mease PJ, Gladman DD, Ritchlin CT et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheu 2005 52 : 3279 3289.
24. Menter A, Tyring SK, Gordon K et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008 58 : 106 115.
25. Saurat JH, Stingl G, Dubertret L et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008 158 : 558 566.
26. Mazzotta A, Esposito M, Costanzo A et al. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study. Am J Clin Dermatol 2009 10 : 319 324.